The role of podocyte injury in chronic kidney disease

Japanese Journal of Clinical Immunology

Volumn 38, Issue 1, 2015, Pages 26-36

  Asanuma, Katsuhiko ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Dendrin; Glomerulosclerosis; Notch2; Podocyte; Proteinuria

Indexed keywords

ARTICLE; CELL DAMAGE; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; END STAGE RENAL DISEASE; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; PODOCYTE; PROTEIN DEPLETION; PROTEINURIA; CYTOLOGY; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC;

DENDRIN; NERVE PROTEIN; NOTCH2 PROTEIN, HUMAN; NOTCH2 RECEPTOR;

GLOMERULAR BASEMENT MEMBRANE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; NERVE TISSUE PROTEINS; PODOCYTES; PROTEINURIA; RECEPTOR, NOTCH2; RENAL INSUFFICIENCY, CHRONIC;

EID: 84924354333     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.38.26     Document Type: Article

References (46)

1. Mundel, P., Kriz, W.: Structure and function of podocytes: an update. Anat Embryol (Berl). 192: 385-397, 1995.
2. Asanuma, K., Mundel, P.: The role of podocytes in glomerular pathobiology. Clin Exp Nephrol. 7: 255-259, 2003.
3. Faul, C., et al.: Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol.17: 428-437, 2007.
4. Asanuma, K., et al.: The role of podocytes in pro-teinuria. Nephrology (Carlton). 12: S15-20, 2007.
5. Lehtonen, S., et al.: Cell junction-associated proteins IQGAP1, MAGI-2, CASK, spectrins, and alpha-actinin are components of the nephrin multi-protein complex. Proc Natl Acad Sci U S A. 102: 9814-9819, 2005.
6. Ihara, K., et al.: MAGI-2 is critical for the formation and maintenance of the glomerular filtration barrier in mouse kidney. Am J Pathol.184:2699-2708, 2014.
7. Asanuma, K., et al.: Dendrin location in podocytes is associated with disease progression in animal and human glomerulopathy. Am J Nephrol. 33: 537-549, 2011.
8. Kriz, W., Lemley, K.V: A Potential Role for Mechanical Forces in the Detachment of Podocytes and the Progression of CKD. J Am Soc Nephrol. 2014.
9. Kriz, W., et al.: Progression of glomerular diseases: is the podocyte the culprit? Kidney Int. 54: 687-697, 1998.
10. Suzuki, T., et al.: Genetic podocyte lineage reveals progressive podocytopenia with parietal cell hyper-plasia in a murine model of cellular/collapsing focal segmental glomerulosclerosis. Am J Pathol.174: 1675-1682, 2009.
11. Matsusaka, T., et al.: Podocyte injury damages other podocytes. J Am Soc Nephrol.22:1275-1285, 2011.
12. Asanuma, K., et al.: Nuclear relocation of the nephrin and CD2AP-binding protein dendrin promotes apoptosis of podocytes. Proc Natl Acad Sci U S A. 104: 10134-10139, 2007.
13. Shankland, S.J.: The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int. 69: 2131-2147, 2006.
14. Shih, N.Y., et al.: CD2AP localizes to the slit diaphragm and binds to nephrin via a novel C-terminal domain. Am J Pathol. 159: 2303-2308, 2001.
15. Huber, T.B., et al.: Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling. Mol Cell Biol. 23: 4917-4928, 2003.
16. Schiffer, M., et al.: A novel role for the adaptor molecule CD2-associated protein in transforming growth factor-beta-induced apoptosis. J Biol Chem.279: 37004-37012, 2004.
17. Yaddanapudi, S., et al.: CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival. J Clin Invest. 121: 3965-3980, 2011.
18. Campbell, K.N., et al.: Yes-associated protein (YAP) promotes cell survival by inhibiting proapoptotic dendrin signaling. J Biol Chem.288: 17057-17062, 2013.
19. Kawata, A., et al.: CIN85 is localized at synapses and forms a complex with S-SCAM via dendrin. J Biochem. 139: 931-939, 2006.
20. Kodama, F., et al.: Translocation of dendrin to the podocyte nucleus in acute glomerular injury in patients with IgA nephropathy. Nephrol Dial Transplant. 28: 1762-1772, 2013.
21. Hara, M., et al.: Urinary podocytes in primary focal segmental glomerulosclerosis. Nephron. 89: 342-347, 2001.
22. Hara, M., et al.: Urinary excretion of podocytes reflects disease activity in children with glomerulonephritis. Am J Nephrol.18: 35-41, 1998.
23. Jefferson, J.A., et al.: Podocyte biology for the bedside. Am J Kidney Dis.58: 835-845, 2011.
24. Asao, R., et al.: Relationships between levels of urinary podocalyxin, number of urinary podocytes, and histologic injury in adult patients with IgA nephropathy. Clin J Am Soc Nephrol. 7:1385-1393, 2012.
25. Hara, M., et al.: Apical cell membranes are shed into urine from injured podocytes: a novel phenomenon of podocyte injury. J Am Soc Nephrol.16: 408-416, 2005.
26. Nielsen, J.S., McNagny, K.M.: The role of podoca-lyxin in health and disease. J Am Soc Nephrol.20: 1669-1676, 2009.
27. Hara, M., et al.: Podocyte membrane vesicles in urine originate from tip vesiculation of podocyte microvilli. Hum Pathol. 41: 1265-1275, 2010.
28. Kanno, K., et al.: Urinary sediment podocalyxin in children with glomerular diseases. Nephron Clin Pract. 95: c91-99, 2003.
29. Hara, M., et al.: Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin. Diabetologia. 55: 2913-2919, 2012.
30. Bao, H., et al.: Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 19: 2001-2010, 2008.
31. Iijima, K., et al.: Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 384: 1273-1281, 2014.
32. Shalhoub, R.J.: Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet. 2: 556-560, 1974.
33. Fornoni, A., et al.: Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 3: 85ra46, 2011.
34. Wofsy, D., et al.: Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum.64: 3660-3665, 2012.
35. Reiser, J., et al.: Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest. 113: 1390-1397, 2004.
36. Yu, C.C., et al.: Abatacept in B7-1-positive pro-teinuric kidney disease. N Engl J Med. 369:2416-2423, 2013.
37. Lydia, A., et al.: Effects of 22-oxa-calcitriol on podocyte injury in adriamycin-induced nephrosis. Am J Nephrol. 35: 58-68, 2012.
38. Stumpf, W.E., et al.: Target cells for 1,25-dihydro-xyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science. 206: 1188-1190, 1979.
39. Artavanis-Tsakonas, S., et al.: Notch signaling: cell fate control and signal integration in development. Science. 284: 770-776, 1999.
40. Schweisguth, F.: Regulation of notch signaling activity. Curr Biol. 14: R129-138, 2004.
41. Chen, L., Al-Awqati, Q.: Segmental expression of Notch and Hairy genes in nephrogenesis. Am J Physiol Renal Physiol. 288: F939-952, 2005.
42. McCright, B., et al.: Defects in development of the kidney, heart and eye vasculature in mice homozygous for a hypomorphic Notch2 mutation. Development.128: 491-502, 2001.
43. McLaughlin, K.A., et al.: Notch regulates cell fate in the developing pronephros. Dev Biol. 227: 567-580, 2000.
44. Cheng, H.T., et al.: Notch2, but not Notch1, is required for proximal fate acquisition in the mammalian nephron. Development.134: 801-811, 2007.
45. Niranjan, T., et al.: The Notch pathway in podo-cytes plays a role in the development of glomerular disease. Nat Med. 14: 290-298, 2008.
46. Tanaka, E., et al.: Notch2 activation ameliorates nephrosis. Nat Commun. 5: 3296, 2014.